Artiva Biotherapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Fred Aslan, Chief Executive Officer and a Director of Artiva Biotherapeutics, Inc., reported multiple transactions in common stock on September 15, 2026.
NASDAQ
Fred Aslan, Chief Executive Officer and a Director of Artiva Biotherapeutics, Inc., reported multiple transactions in common stock on September 10, 2026.
NASDAQ
Ra Capital Management, L.P. and 5 others reported changes in beneficial ownership of Artiva Biotherapeutics, Inc. common stock on September 10, 2026.
NASDAQ
Laura Stoppel, a Director of Artiva Biotherapeutics, Inc., received 16,250 shares of common stock on September 10, 2026.
NASDAQ
Elaine K. Sorg, a Director of Artiva Biotherapeutics, Inc., received 16,250 shares of common stock on September 10, 2026.
NASDAQ
Elizabeth L Hougen, a Director of Artiva Biotherapeutics, Inc., received 16,250 shares of common stock on September 10, 2026.
NASDAQ
Brian Daniels, a Director of Artiva Biotherapeutics, Inc., received 16,250 shares of common stock on September 10, 2026.
NASDAQ
Daniel G. Baker, a Director of Artiva Biotherapeutics, Inc., received 16,250 shares of common stock on September 10, 2026.
NASDAQ
Alison Moore, a Director of Artiva Biotherapeutics, Inc., received 16,250 shares of common stock on September 10, 2026.
NASDAQ
Gines Diego Miralles, President & Head of R&D of Artiva Biotherapeutics, Inc., reported multiple transactions in common stock on September 9, 2026.
NASDAQ
Christopher Horan, Chief Tech Operations Officer of Artiva Biotherapeutics, Inc., reported multiple transactions in common stock on September 9, 2026.
NASDAQ
Jennifer Bush, COO, CLO, Compliance Officer of Artiva Biotherapeutics, Inc., reported multiple transactions in common stock on September 9, 2026.
NASDAQ
Subhashis Banerjee, Chief Medical Officer of Artiva Biotherapeutics, Inc., reported multiple transactions in common stock on September 9, 2026.
NASDAQ
Ra Capital Management, L.P. and 5 others reported changes in beneficial ownership of Artiva Biotherapeutics, Inc. common stock on September 8, 2026.
NASDAQ
Laura Stoppel, a Director of Artiva Biotherapeutics, Inc., received 13,750 shares of common stock on September 8, 2026.
NASDAQ
Elaine K. Sorg, a Director of Artiva Biotherapeutics, Inc., received 13,750 shares of common stock on September 8, 2026.
NASDAQ
Elizabeth L Hougen, a Director of Artiva Biotherapeutics, Inc., received 13,750 shares of common stock on September 8, 2026.
NASDAQ
Brian Daniels, a Director of Artiva Biotherapeutics, Inc., received 13,750 shares of common stock on September 8, 2026.
NASDAQ
Daniel G. Baker, a Director of Artiva Biotherapeutics, Inc., received 13,750 shares of common stock on September 8, 2026.
NASDAQ
Alison Moore, a Director of Artiva Biotherapeutics, Inc., received 13,750 shares of common stock on September 8, 2026.
NASDAQ
Christopher Horan, Chief Tech Operations Officer of Artiva Biotherapeutics, Inc., sold 10,366 shares of common stock on September 3, 2026 for $11.16 per share.
NASDAQ
Jennifer Bush, COO, CLO, Compliance Officer of Artiva Biotherapeutics, Inc., sold 8,391 shares of common stock on September 3, 2026 for $11.16 per share.
NASDAQ
Subhashis Banerjee, Chief Medical Officer of Artiva Biotherapeutics, Inc., sold 1,100 shares of common stock on September 3, 2026 for $11.16 per share.
NASDAQ
Fred Aslan, Chief Executive Officer and a Director of Artiva Biotherapeutics, Inc., sold 61,888 shares of common stock on September 3, 2026 for $11.16 per share.
NASDAQ
Subhashis Banerjee, Chief Medical Officer of Artiva Biotherapeutics, Inc., sold 8,222 shares of common stock on August 27, 2026 for $12.01 per share.
NASDAQ
Subhashis Banerjee, Chief Medical Officer of Artiva Biotherapeutics, Inc., sold 429 shares of common stock on August 18, 2026 for $12.00 per share.
NASDAQ
Ra Capital Management, L.P. and 5 others reported changes in beneficial ownership of Artiva Biotherapeutics, Inc. common stock on July 29, 2026.
NASDAQ
Ra Capital Management, L.P. and 5 others reported changes in beneficial ownership of Artiva Biotherapeutics, Inc. common stock on July 24, 2026.
NASDAQ
Ra Capital Management, L.P. and 5 others reported changes in beneficial ownership of Artiva Biotherapeutics, Inc. common stock on July 21, 2026.
NASDAQ
Ra Capital Management, L.P. and 5 others reported changes in beneficial ownership of Artiva Biotherapeutics, Inc. common stock on July 13, 2026.